Methylthioninium chloride: Pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass

Anaesthesia

Volumn 60, Issue 6, 2005, Pages 575-587

  Faber, P ^a   Ronald, A ^a   Millar, B W ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; METHYLAMMONIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASODILATOR AGENT;

BLOOD CLOTTING; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CELL INTERACTION; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; ENDOTHELIUM; ENZYME INHIBITION; EXTRACORPOREAL CIRCULATION; HEMOLYSIS; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATION; INHIBITION KINETICS; INTENSIVE CARE UNIT; METHEMOGLOBINEMIA; MORBIDITY; NAUSEA; NONHUMAN; PREGNANCY; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SEPTICEMIA; THORAX PAIN; THROMBOCYTE; TOXICITY TESTING; VASODILATATION; VASOPLEGIC SYNDROME; VOMITING;

ADULT; ANIMALS; CARDIOPULMONARY BYPASS; CHILD; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOTENSION; INFANT, NEWBORN; METHYLENE BLUE; NITRIC OXIDE; POSTOPERATIVE COMPLICATIONS; PREGNANCY; SEPSIS; SHOCK; VASODILATION;

EID: 19944380781     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2005.04185.x     Document Type: Review

References (162)

1. Gomes WJ, Carvalho AC, Palma JH, Goncalves I Jr, Buffolo E. Vasoplegic syndrome: a new dilemma. Journal of Thoracic and Cardiovascular Surgery 1994; 107: 942-3.
2. Myles PS, Leong CK, Currey J. Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia 1997; 11: 571-4.
3. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia 1997; 11: 355-66.
4. Martindale. The Complete Drug Reference, 33rd edn. London: Pharmaceutical Press, 2002.
5. VWR. VWR International Material Safety Data Sheet. Poole: VWR International Ltd [WWW document] http://uk.vwr.com/app/MSDS?uri=/html/gb_msds/106045.pdf).
6. DiSanto AR, Wagner JG. Pharmacokinetics of highly ionised drugs II. Methylene blue - absorption, metabolism, and excretion in man and dog after oral administration. Journal of Pharmaceutical Sciences 1972; 61: 1086-90.
7. Clifton J 2nd, Leikin JB. Methylene blue. American Journal of Therapeutics 2003; 10: 289-91.
8. Peter C, Hongwan D, Kuepfer A, Lauterberg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. European Journal of Clinical Pharmacology 2000; 56: 247-50.
9. DiSanto AR, Wagner JG. Pharmacokinetics of highly ionised drugs I. Methylene blue - whole blood, urine, and tissue assays. Journal of Pharmaceutical Sciences 1972; 61: 598-02.
10. Sparicio D, Landoni G, Zangrillo A. Angiotensin-converting enzyme inhibitors predispose to hypotension refractory to norepinephrine but responsive to methylene blue. Journal of Thoracic and Cardiovascular Surgery 2004; 127: 608.
11. Leyh RG, Kofidis T, Strueber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery 2003; 125: 1426-31.
12. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Annals of Thoracic Surgery 2004; 77: 496-9.
13. Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD. Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Medicine 1992; 18: 309-11.
14. Evgenov OV. Administration of methylene blue in human septic shock: renaissance of an old drug? Critical Care Medicine 2003; 31: 1601-2.
15. Kofidis T, Strueber M, Wilhelmi M, et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. Journal of Thoracic and Cardiovascular Surgery 2001; 122: 823-4.
16. Evora PRB, Levin RL. Methylene blue as drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery 2004; 127: 895-6.
17. Preiser JC, Lejeune P, Roman A, et al. Methylene blue in septic shock: a clinical trial. Critical Care Medicine 1995; 23: 259-64.
18. Kirov MY, Evgenov OV, Evegnov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomised, controlled study. Critical Care Medicine 2001; 29: 1860-7.
19. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. Journal of Thoracic and Cardiovascular Surgery 2003; 125: 426-7.
20. Evora PR, Oliveira NAM, Duarte NM, Vincente WV. Methylene blue as treatment for contrast medium-induced anaphylaxis. Journal of Postgraduate Medicine 2002; 48: 327-8.
21. Aeschlimann C, Kupfer A, Schefer H, Cerny T. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metabolism and Disposition 1998; 26: 883-90.
22. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. British Journal of Cancer 2000; 82: 291-4.
23. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. New England Journal of Medicine 1995; 332: 1239-40.
24. Burrows GE. Methylene blue: effects and disposition in sheep. Journal of Veterinary Pharmacology and Therapeutics 1984; 7: 225-31.
25. Zhang H, Rogiers P, Preiser JC, et al. Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Critical Care Medicine 1995; 23: 1711-21.
26. Liao YP, Hung DZ, Yang DY. Hemolytic anemia after methylene blue therapy for aniline-induced methemoglobinemia. Veterinary and Human Toxicology 2002; 44: 19-21.
27. Harvey JW, Keitt AS. Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinaemia. British Journal of Haematology 1983; 54: 29-41.
28. Miller MJ, Sandoval M. Nitric oxide. III. A molecular approach to intestinal inflammation. American Journal of Physiology 1999; 276: G795-9.
29. Driscoll W, Thurin S, Carrion V, Steinhorn RH, Morin FC. Effect of methylene blue on refractory neonatal hypotension. Journal of Pediatrics 1996; 129: 904-8.
30. Troche BI. The methylene blue baby. New England Journal of Medicine 1989; 320: 1756-7.
31. Serota FT, Bernbaum JC, Schwartz E. The methylene-blue baby. Lancet 1979; 24: 1142-3.
32. Kessler MR, Eide T, Humayun B, Poppers PJ. Spurious pulse oximeter desaturation with methylene blue injection. Anaesthesiology 1986; 54: 435-6.
33. Blass N, Fung D. Dyed but not dead - methylene blue overdose. Anaesthesiology 1976; 45: 458-9.
34. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochemical Pharmacology 1993; 45: 367-74.
35. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. European Heart Journal 1993; 14: 22-6.
36. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrate, and amyl nitrite. Canadian Journal of Physiology and Pharmacology 1981; 59: 150-6.
37. Gruetter CA, Gruetter DY, Lyon JE, Kadowitz PJ, Ignarro LJ. Relationship between cyclic guanosine 3,5-monophosphate formation and relaxation of coronary smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide. effects of methylene blue and methemoglobin. Journal of Pharmacology and Experimental Therapeutics 1981; 219: 181-6.
38. Gerzer R, Boehm E, Hofmann F, Schultz G. Soluble guanylate cyclase purified from bovine lung contains heme and copper. FEBS Letters 1981; 132: 71-4.
39. Ohlstein EH, Woods KS, Ignarro LJ. Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme and protoporphyrin IX. Archives of Biochemistry and Biophysics 1982; 218: 187-98.
40. Singh S, Evans TW. Nitric oxide, the biological mediator of the decade: fact or fiction? European Respiratory Journal 1997; 10: 699-707.
41. Kumar A, Brar R, Wang P, et al. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. American Journal of Physiology 1999; 276: R265-76.
42. Martin W, Drazan KM, Newby AC. Methylene blue but not changes in cyclic GMP inhibits resting and bradykinin-stimulated production of prostacyclin by pig aortic endothelial cells. British Journal of Pharmacology 1989; 97: 53-6.
43. Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Medicine 1995; 21: 1027-31.
44. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Annals of Thoracic Surgery 2003; 75: S715-20.
45. Speziale G, Ruvolo G, Marino B. A role for nitric oxide in the vasoplegic syndrome. Journal of Cardiovascular Surgery 1996; 37: 301-3.
46. Downing SW, Edmunds LHJr. Release of vasoactive substances during cardiopulmonary bypass. Annals of Thoracic Surgery 1992; 54: 1236-43.
47. McDonald LJ, Murad F. Nitric oxide and cyclic GMP signalling. Proceedings of the Society for Experimental Biology and Medicine 1996; 211: 1-6.
48. Wang Y, Marsden PA. Nitric oxide synthases: biochemical and molecular regulation. Current Opinions in Nephrology and Hypertension 1995; 4: 12-22.
49. G-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from 1-arginine. Journal of Biological Chemistry 1991; 266: 6259-63.
50. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide. Anaesthesiology 1999; 91: 1090-21.
51. Bredt DS, Snyder SH. Isolation of nitric oxidase, a calmodulin-requiring enzyme. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 682-5.
52. Christopherson KS, Bredt DS. Nitric oxide in excitable tissues: physiological roles and disease. Journal of Clinical Investigation 1997; 100: 2424-9.
53. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990; 347: 768-70.
54. Palmer PM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
55. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Review 1991; 43: 109-42.
56. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 6348-52.
57. Hibbs JB Jr, Vavrin Z, Taintor RR. L-Arginine is required for the expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. Journal of Immunology 1987; 138: 550-65.
58. Busse R, Muelsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Letters 1990; 275: 87-90.
59. Gross SS, Jaffe EA, Levi R, Kilbourn RG. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochemical and Biophysical Research Communications 1991; 178: 823-9.
60. Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli liposaccharide. Proceedings of the National Academy of Sciences of the United States of America 1985; 82: 7738-42.
61. G-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Critical Care Medicine 1994; 22: 1835-40.
62. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 3629-32.
63. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991; 338: 732-6.
64. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB Journal 1993; 7: 328-38.
65. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochimica et Biophysica Acta 1993; 1178: 153-75.
66. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. Journal of Clinical Investigation 1986; 78: 1-5.
67. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. Journal of Biological Chemistry 2002; 277: 3310-7.
68. Sanchez LS, de la Monte SM, Filippov G, et al. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatric Research 1998; 43: 163-8.
69. Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. Journal of the American College of Cardiology 2002; 40: 1232-40.
70. Hosogai N, Tomita M, Hamada K, Ogawa T, Hirosumi J, Manda T. Phosphodiesterase type 5 inhibition ameliorates nephrotoxicity induced by cyclosporin A in spontaneous hypertensive rats. European Journal of Pharmacology 2003; 477: 171-8.
71. Palmer RM. The discovery of nitric oxide in the vessel wall. A unifying concept in the pathogenesis of sepsis. Archives of Surgery 1993; 128: 396-01.
72. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circulatory Shock 1993; 41: 77-81.
73. Winlaw DS, Smythe GA, Keogh AM, et al. Increased nitric oxide production in heart failure. Lancet 1994; 344: 373-4.
74. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Annals of International Medicine 2002; 136: 515-22.
75. McMahon TJ, Ignarro LJ, Kadowitz PJ. Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. Journal of Applied Physiology 1993; 74: 1704-11.
76. Johnstone MT, Lam JYT, Lacoste L, et al. Methylene blue inhibits the anti-thrombotic effect of nitroglycerin. Journal of the American College of Cardiology 1993; 20: 255-9.
77. Diodati J, Theroux P, Latour JG, et al. Effect of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and unstable angina. American Journal of Cardiology 1990; 66: 683-8.
78. 2+/calmodulin-regulated nitric oxide synthases. Cell Calcium 1992; 13: 427-34.
79. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; ii: 1057-8.
80. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. British Journal of Pharmacology 1986; 88: 411-5.
81. Shafer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980; 55: 649-54.
82. 2 after low-dose nitroglycerin. Thrombosis Research 1981; 23: 59-67.
83. Salvemini D, Currie MG, Mollace V. Nitric oxide-mediated cyclooxygenase activation. Journal of Clinical Investigation 1996; 97: 2562-8.
84. Coleman RA, Smith WL, Narumiay S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacology Review 1994; 46: 205-29.
85. Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related nitrous compounds in vitro and in vivo and their relevance to cardiovascular disorders. Journal of the American College of Cardiology 1991; 18: 1529-36.
86. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. New England Journal of Medicine 1990; 323: 27-36.
87. Wen FQ, Watanabe K, Yoshida M. Nitric oxide enhances PGI2 production by human pulmonary artery smooth muscle cells. Prostaglandins, Leukotrienes and Essential Fatty Acids 2000; 62: 369-78.
88. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGI) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13: 389-97.
89. Levin RI, Jaffe EA, Weksler BB. Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. Journal of Clinical Investigation 1981; 67: 762-9.
90. De Leval X, Hanson J, David JL, et al. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Current Medicinal Chemistry 2004; 11: 1243-52.
91. Harbrecht BG, Stadler J, Demetris AJ, Simmons RL, Billiar TR. Nitric oxide and Prostaglandins interact to prevent hepatic damage during murine endotoxemia. American Journal of Physiology 1994; 266: G1004-10.
92. Okamura T, Yoshida K, Toda N. Suppression by methylene blue of prostaglandin I2 in isolated dog renal arteries. Journal of Pharmacology and Experimental Therapeutics 1990; 254: 198-203.
93. Okatani Y, Watanabe K, Nakano Y, Sagara Y. Relaxant effect of nitric oxide and prostacyclin on serotonin-induced vasoconstriction of human umbilical artery. Acta Obstetrica et Gynecologica Scandinavica 1996; 75: 108-12.
94. Magness RR, Rosenfeld CR, Hassan A, Shaul PW. Endothelial vasodilator production by uterine and systemic arteries. I. Effects of ANGII on PGI2 and NO in pregnancy. American Journal of Physiology 1996; 270: H1914-23.
95. Danesh J, Muir J, Wong YK, et al. Risk factors for coronary heart disease and acute-phase proteins: a population-based study. European Heart Journal 1999; 20: 954-9.
96. Anfossi G, Russo I, Massucco P, et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. European Journal of Clinical Investigation 2004; 34: 482-9.
97. Sloand EM, Kessler CM, McIntosh CL, Klein HG. Methylene blue for neutralization of heparin. Thrombosis Research 1989; 54: 677-86.
98. Kikura M, Lee MK, Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesthesia and Analgesia 1996; 83: 223-7.
99. Metz S, Horrow JC, Goeil IP, Kuretu ML, Bellwoar C. Methylene blue does not neutralize heparin after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia 1996; 10: 474-6.
100. Evgenov OV, Sveinbjornsson B, Bjertnaes LJ. Continuously infused methylene blue modulates the early cardiopulmonary response to endotoxin in awake sheep. Acta Anaesthesiologica Scandinavica 2001; 45: 1246-54.
101. Evgenov OV, Sager G, Bjertnases LJ. Methylene blue reduces lung fluid filtration during the early phase of endotoxemia in awake sheep. Critical Care Medicine 2001; 29: 374-9.
102. Keaney JFJr, Puyana JC, Francis S, et al. Methylene blue reverses endotoxin-induced hypotension. Circulation Research 1994; 74: 1121-5.
103. Schultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. Journal of Clinical Investigation 1992; 90: 1718-25.
104. Avontuur JAM, Bruining HA, Ince C. Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circulation Research 1995; 76: 418-25.
105. Harbrecht BG, Wu B, Watkins SC, et al. Inhibition of nitric oxide synthase during hemorrhagic shock increases hepatic injury. Shock 1995; 4: 332-7.
106. Daemen-Gubbels CRGH, Groeneveld PHP, Groeneveld ABJ, et al. Methylene blue increases myocardial function in septic shock. Critical Care Medicine 1995; 23: 1363-70.
107. Nava E, Palmer RMJ. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 1991; 338: 1555-7.
108. Avontuur JAM, Nolthenius RPT, van Bodegom JW, Bruining HA. Prolonged inhibition of nitric oxide synthesis in severe sepsis: a clinical study. Critical Care Medicine 1998; 26: 660-7.
109. Schneider F. Methylene blue infusion in septic shock. Critical Care Medicine 1995; 23: 1935-6.
110. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery 1983; 86: 845-57.
111. Van der Kamp KW, van Oeveren W. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery. International Journal of Artificial Organs 1993; 16: 836-42.
112. Kaplan AP. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation. Federation Proceedings 1983; 42: 3123-7.
113. Strukova SM, Dugina TN, Khlgatian SV, et al. Thrombin-mediated events implicated in mast cell activation. Seminars in Thrombosis and Hemostasis 1996; 22: 145-50.
114. Johnson K, Choi Y, DeGroot E, et al. Potential mechanisms for a pro-inflammatory vascular cytokine response to coagulation activation. Journal of Immunology 1998; 160: 5130-5.
115. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signalling by serine proteases. American Journal of Physiology 1998; 274: C1429-52.
116. Sugama Y, Tiruppathi C, Offakidevi K, et al. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. Journal of Cell Biology 1992; 119: 935-44.
117. Parthasarathy N, Torti SV, Torti FM. Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochemical Journal 2002; 365: 279-83.
118. Zhao Y, Qui Q, Mahdi F, et al. Assembly and activation of HK-PK complex on endothelial cells result in bradykinin liberation and NO formation. American Journal of Physiology 2001; 280: H1821-9.
119. Ascione R, Loyd CT, Underwood MJ, et al. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Annals of Thoracic Surgery 2000; 69: 1198-204.
120. Seghaye MC, Duchateau J, Grabitz RG, et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. Journal of Thoracic and Cardiovascular Surgery 1993; 106: 978-87.
121. Bruins P, te Velhuis H, Eerenberg-Belmer AJ, et al. Heparin-protamine complexes and C-reactive protein induced activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thrombosis and Haemostasis 2000; 84: 237-43.
122. Soulika AM, Khan MM, Hattori T, et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clinical Immunology 2000; 96: 212-21.
123. Tofukuji M, Stahl GL, Agah A, et al. Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced endothelial dysfunction. Journal of Thoracic and Cardiovascular Surgery 1998; 16: 1060-8.
124. Del Balzo U, Engler RL, Ito BR. Complement C5a-mediated myocardial ischemia and neutrophil sequestration: two independent phenomena. American Journal of Physiology 1993; 264: H336-44.
125. Montalto MC, Hart ML, Jordan JE, Wada K, Stahl GL. Role for complement in mediating intestinal nitric oxide synthase-2 and superoxide dismutase expression. American Journal of Physiology 2003; 285: G197-206.
126. Aktan F. iNos-mediated nitric oxide production and its regulation. Life Sciences 2004; 75: 639-53.
127. Nilsson L, Brunnkvist S, Nilsson U, et al. Activation of inflammatory systems during cardiopulmonary bypass. Scandinavian Journal of Thoracic and Cardiovascular Surgery 1988; 22: 51-3.
128. Seghaye MC, Grabitz RG, Duchateau J, et al. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. Journal of Thoracic and Cardiovascular Surgery 1996; 112: 687-97.
129. Jordan JE, Zhao, ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovascular Research 1999; 43: 860-78.
130. Brasil LA, Gomes WJ, Salomao R, Buffolo E. Inflammatory response after myocardial revascularisation with or without cardiopulmonary bypass. Annals of Thoracic Surgery 1998; 66: 56-9.
131. Hill GE. Cardiopulmonary bypass-induced inflammation: is it important? Journal of Cardiothoracic and Vascular Anesthesia 1998; 12: S21-5.
132. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utine JG. Endotoxemia associated with cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery 1987; 93: 832-7.
133. Strueber M, Cremer JT, Gohrbandt B, et al. Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass. Annals of Thoracic Surgery 1999; 68: 1330-5.
134. Menasche P, Haydar S, Peynet J, et al. A potential mechanism of vasodilation after warm heart surgery: the temperature-dependent release of cytokines. Journal of Thoracic and Cardiovascular Surgery 1994; 107: 293-9.
135. Casey WF, Hauser GJ, Hannallah RS, Midgley FM, Khan WN. Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Critical Care Medicine 1992; 20: 1090-6.
136. Rothenburger M, Soeparwata R, Deng MC, et al. The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. Journal of the American College of Cardiology 2001; 38: 124-30.
137. Roth-Isigkeit A, Hasselbach L, Ocklitz E, et al. Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass. Clinical and Experimental Immunology 2001; 125: 80-8.
138. Tomasdottir H, Hjartason H, Ricksten A, et al. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesthesia and Analgesia 2003; 97: 944-9.
139. Wan S, LeClerc JL, Vincent JL. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Annals of Thoracic Surgery 1997; 63: 269-76.
140. Deng MC, Dasch B, Erren M, Mollhoff T, Scheld HH. Impact of left ventricular dysfunction on cytokines, hemodynamics and outcome in bypass grafting. Annals of Thoracic Surgery 1996; 62: 184-90.
141. Aydin NB, Gercekoglu H, Aksu B, et al. Endotoxemia in coronary artery bypass surgery: a comparison of the off-pump technique and conventional cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery 2003; 125: 843-8.
142. Gulielmos V, Menschikowski M, Dill HM, et al. Interleukin-1, interleukin-6 and myocardial enzyme response after coronary artery bypass grafting - a prospective randomised comparison of the conventional and three minimally invasive surgical techniques. European Journal of Cardiothoracic Surgery 2000; 18: 594-601.
143. Cavaillon JM, Fitting C, Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. European Journal of Immunology 1990; 20: 253-7.
144. Perlmutter DH, Dinarrello CA, Punsal PI, Colten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. Journal of Clinical Investigation 1986; 78: 1349-54.
145. Hattori Y, Hattori S, Kasai K. Lipopolysaccharide activates Akt in vascular smooth muscle cells resulting in induction of inducible nitric oxide synthase through nuclear factor-kappa B activation. European Journal of Pharmacology 2003; 481: 153-8.
146. Nagao K, Takenaka S, Yamaji R, Inui H, Nakano Y. Nitric oxide synthase induction, cGMP elevation, and biopterin synthesis in vascular smooth muscle cells stimulated with interleukin-1 beta in hypoxia. Journal of Biochemistry 2003; 133: 501-5.
147. Lim S, Kang KW, Park SY, et al. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase expression by a novel compound, mercaptopyrazine, through suppression of nuclear factor-kappa B binding to DNA. Biochemical Pharmacology 2004; 68: 719-28.
148. Singh AK, Jiang Y. How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology 2004; 201: 197-07.
149. Gu YJ, Mariani MA, van Oeveren W, Grandjean JG, Boonstra PW. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Annals of Thoracic Surgery 1998; 65: 420-4.
150. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. Journal of the American Medical Association 1994; 271: 226-33.
151. Andersen LW, Baek L, Degn H, et al. Presence of circulating endotoxins during cardiac operations. Journal of Thoracic and Cardiovascular Surgery 1987; 93: 115-9.
152. Gomes WJ, Carvalho AC, Palma JH, et al. Vasoplegic syndrome after open heart surgery. Journal of Cardiovascular Surgery 1998; 39: 619-23.
153. Gomes WJ, Erlichman MR, Atista-Filho ML, et al. Vasoplegic syndrome after off-pump coronary artery bypass surgery. European Journal of Cardiothoracic Surgery 2003; 23: 165-9.
154. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. Journal of Cardiac Surgery 2000; 15: 347-53.
155. Byrne JG, Leacche M, Paul S, et al. Risk factors and outcomes for 'vasoplegic syndrome' following cardiac transplantation. European Journal of Cardiothoracic Surgery 2004; 25: 327-32.
156. Mekontso-Dessap A, Houl R, Soustelle C, et al. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Annals of Thoracic Surgery 2001; 71: 1428-32.
157. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Journal of Thoracic and Cardiovascular Surgery 1998; 116: 973-80.
158. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-9.
159. Lamas S, Michel T, Brenner BM, Marsden PA. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF-α. American Journal of Physiology 1991; 261: C634-41.
160. Ruvolo G, Speziale G, Greco E, et al. Nitric oxide release during hypothermic versus normothermic cardiopulmonary bypass. European Journal of Cardiothoracic Surgery 1995; 9: 651-4.
161. Masetti P, Murphy SF, Kouchoukos NT. Vasopressin therapy for vasoplegic syndrome following cardiopulmonary bypass. Journal of Cardiac Surgery 2002; 17: 485-9.
162. Sparicio D, Landoni G, Pappalardo F, et al. Methylene blue for lithium-induced refractory hypotension in off-pump coronary artery bypass graft: report of two cases. Journal of Thoracic and Cardiovascular Surgery 2004; 127: 592-3.